CRISPR Therapeutics AG (CRSP) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code.
Analysis Summary
CRISPR Therapeutics AG reported revenue of $3.5M in the most recent fiscal year, growing at a 5-year CAGR of 37.3%.
Trailing-twelve-month margins: gross margin -15.3%, operating margin -39.7%, net margin -33.7%.
Balance sheet quality for CRSP: current ratio of 13.3, net cash position of $1.58B. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $52.21 |
| Market Cap | $5.0B |
| Exchange | NASDAQ |
| Country | CH |
Valuation Ratios
| Price / Book | 2.86 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -1534.39% |
| Operating Margin | -3971.53% |
| Net Margin | -3368.72% |
Financial Health
| Debt / Equity | 0.45 |
| Current Ratio | 17.85 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | $5.0B | 2.86 | ||
| ARWR | Arrowhead Pharmaceuticals, Inc. | $9.3B | 19.78 | -0.3% | |
| PCVX | Vaxcyte, Inc. | $8.5B | 3.10 | -37.6% | |
| CYTK | Cytokinetics, Incorporated | $9.1B | 119.0% | ||
| KRYS | Krystal Biotech, Inc. | $9.9B | 39.88 | 7.17 | |
| NUVL | Nuvalent, Inc. | $9.1B | 8.30 | ||
| ACLX | Arcellx, Inc. | $6.7B | 16.10 |
Price Performance
| 1 month | -1.43% |
| 3 months | -3.48% |
| Year-to-date | -0.44% |
| 1 year | -11.61% |
| 3 years | +9.59% |
| 5 years | -58.07% |
52-Week Range
| 52-week High | $78.48 |
| 52-week Low | $44.12 |
| Avg Volume (90d) | 1.6M |
Related companies: ACLX · AKRO · ARWR · CYTK · KRYS · MTSR · NUVL
Explore sector: Healthcare · Biotechnology
More sections of CRSP: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks